News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Director of Helix Biopharma (CC:HBP) Acquires A Further 1,000,000 Common Shares



1/13/2014 9:19:26 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

AURORA, ON--(Marketwired - January 10, 2014) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company dedicated to developing drugs for prevention and treatment of cancer, today announced that it has been advised by Dr. Marek Orlowski, a member of the board of directors of Helix and Chairman of the Supervisory Board of Helix Polska, that he has purchased 1,000,000 previously issued and outstanding shares of Helix for a total purchase price of approximately CAD$1.72 million since December 30, 2013.

Dr. Orlowski now holds an aggregate of 1,710,000 shares of Helix.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the symbol "HBP".


Investor Relations:
Helix BioPharma Corp.
Tel : 905 841-2300
Email: ir@helixbiopharma.com



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES